To respond or not to respond to CD40 agonism: That is the prediction

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 83-85

  Shi, Xiaoyan ^a   Dornan, David ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; DACETUZUMAB;

ANTIGEN FUNCTION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DEATH; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84886945383     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.17827     Document Type: Note

References (10)

1. Planken EV, Dijkstra NH, Bakkus M, Willemze R, Kluin-Nelemans JC. Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen. Br J Haematol 1996; 95:319-26.
2. Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 2002; 100:217-23.
3. Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, et al. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med 2011; 3:74.
4. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4371-7.
5. Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NFkappaB pathway and promotes lymphomagenesis. J Exp Med 2008; 205:1317-29.
6. Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, Wang H, et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 2008; 321:663-8.
7. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011; 471:591-6.
8. Lewis TS, McCormick RS, Stone IJ, Emmerton K, Mbow B, Miyamoto J, et al. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 2011; 25:1007-16.
9. Forero-Torres NLB, Nasta SD, Northfelt D, Beaven A, Myint H, Whiting NC, et al. A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2009; 114-586.
10. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-6.